Category: Pharmaceutical Industry
-
AstraZeneca expands cancer drug patent enforcement campaign in U.S., seeks preliminary injunctions
AstraZeneca has filed four separate complaints against generic drugmakers Cipla, Sandoz, Natco, and Zydus in the United States District Court for the District of New Jersey.
-
Catalyst and Teva Pharmaceuticals settle patent dispute over rare-disease drug, but fight for orphan treatment not over yet
Nasadaq-listed Catalyst sees shares rise by 18% following the settlement, which grants Teva a license from February 2035.
-
UPC’s Court of Appeal throws out Alexion’s appeals against Amgen and Samsung Bioepis over validity doubts, reveals €100M value of each dispute
The UPC’s Court of Appeal rejects Alexion’s appeals of decisions to deny preliminary injunctions against Amgen and Samsung Bioepis, where the value of the dispute was set at €100M for each case.
-
Japan’s Nippon Shinyaku vows to fight on in U.S. drug dispute against Sarepta Therapeutics, despite heavy $115 million blow
The Japanese pharma company initiated the drug patent litigation in 2021, but the case eventually boomeranged and a District of Delaware verdict last week ultimately handed Sarepta the win.
-
AstraZeneca defends record patent invalidation claims in China
The UK pharma giant has defeated 33 invalidation claims brought by Chinese generics manufacturers against crystal form patents related to its highest-selling diabetes drug.
-
Pfizer brought UPC revocation action 9 seconds after midnight on grant date, argues Glaxo jumped the gun with infringement filing
Pharmaceutical giants GlaxoSmithKline and Pfizer are embroiled in an interesting UPC venue fight that involves questions of timing.
-
China’s Supreme People’s Court settles mRNA patent, trade secrets litigation under President Xi’s new ‘Fengqiao’ dispute model
Chinese courts are imposing mediation on more and more cases under the new order, including those involving patent infringement.
-
Northwestern University amended license agreement with inventors’ startup, now suing Moderna in Delaware over LNP patents
Northwestern University is suing Moderna over lipid nanoparticle (LNP) patents.
-
UPC’s Dusseldorf LD denies PI in Novartis v. Celltrion: some preparations for product launch aren’t sufficient for imminent infringement
The UPC’s Dusseldorf LD unsurprisingly denied a preliminary injunction motion by Novartis over Celltrion’s preparations for the launch of a biosimilar.
-
UPC’s Paris CD keeps Edwards Lifesciences patent on prosthetic heart valve alive based on late-filed auxiliary request
The UPC’s Paris Central Division has upheld an Edwards Lifesciences patent in an amended form on a procedural basis that will result in an important clarification by the Court of Appeal.